featured
FDA Approves Vyalev for Advanced Parkinson Disease
Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for treatment of motor fluctuations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.